Akebia Therapeutics (AKBA) Cash from Financing Activities (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Cash from Financing Activities of -$926000.0 for Q1 2026, down 101.24% year-over-year from $74.9 million in Q1 2025, and up 80.9% quarter-over-quarter from -$4.8 million in Q4 2025.
Akebia Therapeutics (AKBA) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Cash from Financing Activities for 14 consecutive years, with -$926000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 101.24% year-over-year to -$926000.0; the TTM figure through Mar 2026 stood at -$2.9 million (down 102.77% YoY), while the FY2025 annual figure was $72.9 million, up 46.84% from the prior year.
- Cash from Financing Activities rose to -$926000.0 in Q1 2026 per AKBA's latest filing, from -$4.8 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $74.9 million in Q1 2025 and bottomed at -$32.9 million in Q3 2022.
- Historically, Cash from Financing Activities has averaged $6.5 million across 5 years, with a median of $50000.0 in 2023.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities tumbled 128900.0% — and 2024, when it soared 2346.0%.
- Akebia Therapeutics' Cash from Financing Activities stood at -$1000.0 in 2022, then sank by 128900.0% to -$1.3 million in 2023, then soared by 1830.62% to $22.3 million in 2024, then sank by 121.72% to -$4.8 million in 2025, then jumped by 80.9% to -$926000.0 in 2026.
- Business Quant data shows AKBA's Cash from Financing Activities at -$926000.0 in Q1 2026, -$4.8 million in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn | -6.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.54 Mn |
| Jun 30, 2026 | -6.54 Mn |
| Mar 31, 2026 | -926,000.00 |
| Mar 31, 2026 | -926,000.00 |
| Dec 31, 2025 | -4.85 Mn |
| Dec 31, 2025 | -4.85 Mn |
| Sep 30, 2025 | 1.11 Mn |
| Sep 30, 2025 | 1.11 Mn |
| Jun 30, 2025 | 1.72 Mn |
| Jun 30, 2025 | 1.72 Mn |
| Mar 31, 2025 | 74.94 Mn |
| Mar 31, 2025 | 74.94 Mn |
| Dec 31, 2024 | 22.33 Mn |
| Dec 31, 2024 | 22.33 Mn |
| Sep 30, 2024 | 1.22 Mn |
| Sep 30, 2024 | 1.22 Mn |
| Jun 30, 2024 | 7.64 Mn |
| Jun 30, 2024 | 7.64 Mn |
| Mar 31, 2024 | 18.48 Mn |
| Mar 31, 2024 | 18.48 Mn |